Janux Therapeutics, Inc.

NasdaqGM:JANX 株式レポート

時価総額：US$885.5m

Janux Therapeutics マネジメント

マネジメント 基準チェック /24

Janux Therapeuticsの CEO はDavid Campbellで、 Jun2017年に任命され、 の在任期間は 8.92年です。 の年間総報酬は$ 13.51Mで、 5%給与と95%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.37%を直接所有しており、その価値は$ 3.26M 。経営陣と取締役会の平均在任期間はそれぞれ2年と4.7年です。

主要情報

David Campbell

最高経営責任者

US$13.5m

報酬総額

CEO給与比率5.03%
CEO在任期間8.9yrs
CEOの所有権0.4%
経営陣の平均在職期間2yrs
取締役会の平均在任期間4.7yrs

経営陣の近況

Recent updates

分析記事 • May 13

Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts

Celebrations may be in order for Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders, with the analysts delivering a...
分析記事 • May 11

Janux Therapeutics, Inc. (NASDAQ:JANX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Janux Therapeutics, Inc. ( NASDAQ:JANX ) came out with its quarterly results last week, and we wanted to see how the...
Seeking Alpha • May 04

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

Summary Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runway and validated technology platforms. Discontinuation of JANX008 demonstrates financial discipline, reallocating resources to higher-potential assets and further validating the TRACTr platform. Strategic partnerships with Merck and BMY could yield up to $1.8 billion in milestones plus royalties, supporting long-term value creation. Despite early-stage pipeline risks and near-term volatility, JANX’s cash position and platform progress justify a high-risk, long-term investment thesis. Read the full article on Seeking Alpha
分析記事 • Oct 08

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • Apr 23

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Dec 03

Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause

Summary Janux Therapeutics' TRACTr platform shows promise with encouraging early data, but the high valuation for a phase 1 company makes it a risky investment. The PSMA-targeted JANX007 has shown significant PSA reductions and partial tumor responses, but long-term efficacy and safety remain uncertain. JANX has a strong cash position, reducing immediate financial risks, but the market's high expectations could lead to severe valuation drops if data disappoints. Despite potential buyout rumors, the unproven nature of JANX's technology and the high market cap lead me to maintain a “Strong Sell” rating. Read the full article on Seeking Alpha
分析記事 • Oct 01

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 01

Janux Therapeutics: Buoyed By Buyout Speculation

Summary Today, we take another look at clinical stage biotech concern Janux Therapeutics, whose stock has soared in 2024. The shares have been buoyed throughout most of 2024 by a bevy of buyout speculation and some promising early-stage trial data. The company has a robust balance sheet and is targeting some potentially large markets. However, the company's pipeline is early-stage and there was some significant insider selling in the stock in early June at near all-time highs. Can the rally in Janux Therapeutics continue? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Jul 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 11

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Summary Janux Therapeutics' JANX007 shows promising Phase 1 data in treating advanced prostate cancer, with significant PSA level reductions. Early data suggest JANX007 could meet unmet needs in mCRPC treatment, with potential for dose optimization and safety balance. Amidst takeover speculation, Janux stock's valuation surged, yet I advise caution due to the speculative nature of acquisition outcomes. I recommend a cautious 'Buy' for JANX, highlighting its speculative nature, potential risks in drug development, and competition in the mCRPC market. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Summary Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032. Positive preliminary data also observed for the other phase 1a study using JANX008 for the treatment of patients with EGFR expressing solid tumors. Read the full article on Seeking Alpha
分析記事 • Feb 24

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Dec 29

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Key Insights The projected fair value for Janux Therapeutics is US$18.66 based on 2 Stage Free Cash Flow to Equity...
分析記事 • Nov 04

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Jul 20

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • May 23

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Key Insights The projected fair value for Janux Therapeutics is US$15.07 based on 2 Stage Free Cash Flow to Equity...
分析記事 • Feb 09

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Oct 19

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 09

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Janux Therapeutics press release (NASDAQ:JANX): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022
分析記事 • Jun 05

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Feb 19

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Nov 03

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO報酬分析

Janux Therapeutics の収益と比較して、David Campbell の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$114m

Dec 31 2025US$14mUS$680k

-US$114m

Sep 30 2025n/an/a

-US$102m

Jun 30 2025n/an/a

-US$106m

Mar 31 2025n/an/a

-US$78m

Dec 31 2024US$9mUS$646k

-US$69m

Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$44m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$625k

-US$58m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$6mUS$550k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$8mUS$459k

-US$33m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$812kUS$405k

-US$7m

報酬と市場: Davidの 総報酬 ($USD 13.51M ) は、 US市場 ($USD 3.70M ) の同規模の企業の平均を上回っています。

報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。

CEO

David Campbell (65 yo)

8.9yrs
在職期間
US$13,506,231
報酬

Dr. David Campbell, Ph D serves as President, Chief Executive Officer Co-Founder and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific ca...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
David Campbell
President8.9yrsUS$13.51m0.37%
$ 3.3m
Thomas Diraimondo
Chief Scientific Officer2.3yrsUS$4.35m0.17%
$ 1.5m
Janeen Doyle
Chief Corporate & Business Development Officer1yrUS$4.67mデータなし
Matt Whitmire
Vice President of Finance1.8yrsデータなしデータなし
Maria Dobek
Vice President of Accounting1.8yrsデータなし0.0080%
$ 70.8k
Charles Winter
Chief Technical Officer3.3yrsUS$1.61m0.099%
$ 878.1k
James Pennington
General Counsel & Corporate Secretary4.8yrsデータなしデータなし
William Go
Chief Medical Officerless than a yearデータなしデータなし
2.0yrs
平均在職期間
48yo
平均年齢

経験豊富な経営陣: JANXの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
David Campbell
President8.9yrsUS$13.51m0.37%
$ 3.3m
Vickie Capps
Independent Director5.2yrsUS$389.22k0.12%
$ 1.0m
Ronald Barrett
Independent Chairperson4.7yrsUS$420.78k0.0041%
$ 36.3k
Eric Dobmeier
Independent Director1.8yrsUS$376.09k0.00020%
$ 1.8k
Mark Davis
Member of Scientific Advisory Boardno dataデータなしデータなし
Alana McNulty
Independent Director4.7yrsUS$379.84k0.0041%
$ 36.3k
Julie Michele Cherrington
Member of Scientific Advisory Board1.1yrsデータなしデータなし
Alessandra Cesano
Member of Scientific Advisory Boardless than a yearデータなしデータなし
Natasha Hernday
Independent Director1.8yrsUS$374.22k0%
$ 0
Sheila Gujrathi
Independent Director5.2yrsUS$370.47k0.19%
$ 1.7m
Winston Kung
Independent Director3.7yrsUS$379.84k0.0041%
$ 36.3k
Jake Simson
Independent Director5.2yrsUS$381.59k0%
$ 0
4.7yrs
平均在職期間
62yo
平均年齢

経験豊富なボード: JANXの 取締役会 は 経験豊富 であると考えられます ( 4.7年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/25 08:34
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Janux Therapeutics, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20

アナリスト機関
Etzer DaroutBarclays
Alec StranahanBofA Global Research
Joshua SchimmerCantor Fitzgerald & Co.